insights_auto
Outlook: 45.5% bullish·9.1% bearish
Go to analysischevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
US$ २३०.६२
arrow_downward
-०.८८%(-२.०५) 1D
अक्टोबर १२, १०:१८:५७ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
US$ २३३.१३
High
US$ २३३.६०
Low
US$ २२९.००
Mkt. cap
३०.८६ अरब
Avg. vol.
१४.९२ लाख
Volume
६७.३५ हजार
P/E ratio
३९.२५
52-wk high
US$ ४९५.५५
52-wk low
US$ १९७.८१
EPS
US$ ५.८८
Beta
०.२८
Shares outstanding
१३.३८ करोड
No. of employees
२ हजार
Open
US$ २३३.१३
High
US$ २३३.६०
Low
US$ २२९.००
Mkt. cap
३०.८६ अरब
Avg. vol.
१४.९२ लाख
Volume
६७.३५ हजार
P/E ratio
३९.२५
52-wk high
US$ ४९५.५५
52-wk low
US$ १९७.८१
EPS
US$ ५.८८
Beta
०.२८
Shares outstanding
१३.३८ करोड
No. of employees
२ हजार
News stories
From web sources and news partners
Investing.com
·
२३ घण्टा पहिले
Alnylam EVP Bryan Supran sells $398,855 in shares
Investing.com Nigeria
·
२३ घण्टा पहिले
Form 4 Alnylam Pharmaceuticals Inc For: 11 October By Investing.com
Simply Wall Street
·
१ दिन पहिले
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Yahoo Finance
·
२ दिन पहिले
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.